Organovo Holdings, Inc. (0R02.L)
USD 0.38
(-3.43%)
USD 0.38
(-3.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -5.38 Million USD | -322.08% |
| 2022 | 77 Thousand USD | -94.33% |
| 2021 | 1.35 Million USD | 3412.2% |
| 2020 | -41 Thousand USD | -102.19% |
| 2019 | 1.86 Million USD | -28.4% |
| 2018 | 2.6 Million USD | -26.98% |
| 2017 | 3.57 Million USD | 9.13% |
| 2016 | 3.27 Million USD | 119.81% |
| 2015 | -16.52 Million USD | -33.81% |
| 2014 | -12.35 Million USD | -62.61% |
| 2013 | -7.59 Million USD | -141.88% |
| 2012 | -3.14 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -33 Thousand USD | 19.51% |
| 2023 Q3 | -67 Thousand USD | 4.29% |
| 2023 Q1 | 8000.00 USD | -92.23% |
| 2023 Q2 | -70 Thousand USD | -975.0% |
| 2023 FY | -171 Thousand USD | -322.08% |
| 2023 Q4 | -41 Thousand USD | 38.81% |
| 2022 FY | 77 Thousand USD | -94.33% |
| 2022 Q4 | 103 Thousand USD | 10200.0% |
| 2022 Q3 | 1000.00 USD | -95.45% |
| 2022 Q2 | 22 Thousand USD | 144.0% |
| 2022 Q1 | -50 Thousand USD | -103.44% |
| 2021 Q1 | -24 Thousand USD | -9.09% |
| 2021 Q2 | -35 Thousand USD | -45.83% |
| 2021 FY | 1.35 Million USD | 3412.2% |
| 2021 Q4 | 1.45 Million USD | 4029.73% |
| 2021 Q3 | -37 Thousand USD | -5.71% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q4 | -22 Thousand USD | 94.53% |
| 2020 Q2 | -27.99 Thousand USD | 0.0% |
| 2020 FY | -41 Thousand USD | -102.19% |
| 2020 Q3 | -402 Thousand USD | -1335.71% |
| 2019 Q2 | 966 Thousand USD | 56.56% |
| 2019 FY | 1.86 Million USD | -28.4% |
| 2019 Q4 | 129 Thousand USD | -54.74% |
| 2019 Q3 | 285 Thousand USD | -70.5% |
| 2019 Q1 | 617 Thousand USD | 6.56% |
| 2018 Q1 | 569 Thousand USD | -30.78% |
| 2018 FY | 2.6 Million USD | -26.98% |
| 2018 Q4 | 579 Thousand USD | -9.95% |
| 2018 Q3 | 643 Thousand USD | -21.39% |
| 2018 Q2 | 818 Thousand USD | 43.76% |
| 2017 Q2 | 1.1 Million USD | 59.8% |
| 2017 Q1 | 689 Thousand USD | 9.54% |
| 2017 Q4 | 822 Thousand USD | -14.46% |
| 2017 FY | 3.57 Million USD | 9.13% |
| 2017 Q3 | 961 Thousand USD | -12.72% |
| 2016 Q2 | 983 Thousand USD | 35.96% |
| 2016 Q4 | 629 Thousand USD | -33.01% |
| 2016 FY | 3.27 Million USD | 119.81% |
| 2016 Q1 | 723 Thousand USD | 118.11% |
| 2016 Q3 | 939 Thousand USD | -4.48% |
| 2015 FY | -16.52 Million USD | -33.81% |
| 2015 Q4 | -3.99 Million USD | 6.22% |
| 2015 Q3 | -4.25 Million USD | 4.06% |
| 2015 Q2 | -4.43 Million USD | -15.69% |
| 2015 Q1 | -3.83 Million USD | -13.73% |
| 2014 Q1 | -2.71 Million USD | -14.46% |
| 2014 FY | -12.35 Million USD | -62.61% |
| 2014 Q4 | -3.37 Million USD | -9.41% |
| 2014 Q3 | -3.08 Million USD | 3.02% |
| 2014 Q2 | -3.17 Million USD | -17.09% |
| 2013 FY | -7.59 Million USD | -141.88% |
| 2013 Q2 | -1.59 Million USD | -16.21% |
| 2013 Q1 | -1.37 Million USD | -11.6% |
| 2013 Q4 | -2.37 Million USD | -5.56% |
| 2013 Q3 | -2.24 Million USD | -40.53% |
| 2012 Q1 | 258.97 Thousand USD | 115.81% |
| 2012 Q2 | -636.76 Thousand USD | -345.88% |
| 2012 Q3 | -781.21 Thousand USD | -22.69% |
| 2012 Q4 | -1.23 Million USD | -57.83% |
| 2012 FY | -3.14 Million USD | 0.0% |
| 2011 Q2 | 1677.00 USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q4 | 120 Thousand USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 103.984% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 102.239% |
| Codexis, Inc. | 57.33 Million USD | 109.399% |
| Viridian Therapeutics, Inc. | -1 Million USD | -434.623% |